Display options
Cite
Cavanna L, Seghini P, Di Nunzio C, et al. Gastric cancer with brain metastasis and the role of human epidermal growth factor 2 status. Oncol Lett. 2018;15(4):5787-5791doi: 10.3892/ol.2018.8054.
Cavanna, L., Seghini, P., Di Nunzio, C., Orlandi, E., Michieletti, E., Stroppa, E. M., Mordenti, P., Citterio, C., Vecchia, S., & Zangrandi, A. (2018). Gastric cancer with brain metastasis and the role of human epidermal growth factor 2 status. Oncology letters, 15(4), 5787-5791. https://doi.org/10.3892/ol.2018.8054
Cavanna, Luigi, et al. "Gastric cancer with brain metastasis and the role of human epidermal growth factor 2 status." Oncology letters vol. 15,4 (2018): 5787-5791. doi: https://doi.org/10.3892/ol.2018.8054
Cavanna L, Seghini P, Di Nunzio C, Orlandi E, Michieletti E, Stroppa EM, Mordenti P, Citterio C, Vecchia S, Zangrandi A. Gastric cancer with brain metastasis and the role of human epidermal growth factor 2 status. Oncol Lett. 2018 Apr;15(4):5787-5791. doi: 10.3892/ol.2018.8054. Epub 2018 Feb 14. PMID: 29552209; PMCID: PMC5840578.
Copy Download .nbib Format: NLM
Share it on

Oncol Lett. 2018 Apr;15(4):5787-5791. doi: 10.3892/ol.2018.8054. Epub 2018 Feb 14.

Gastric cancer with brain metastasis and the role of human epidermal growth factor 2 status.

Oncology letters

Luigi Cavanna, Pietro Seghini, Camilla Di Nunzio, Elena Orlandi, Emanuele Michieletti, Elisa Maria Stroppa, Patrizia Mordenti, Chiara Citterio, Stefano Vecchia, Adriano Zangrandi

Affiliations

  1. Department of Oncology and Hematology, Piacenza General Hospital, I-29121 Piacenza, Italy.
  2. Department of Epidemiology, Piacenza General Hospital, I-29121 Piacenza, Italy.
  3. Department of Radiology, Piacenza General Hospital, I-29121 Piacenza, Italy.
  4. Department of Pathology, Piacenza General Hospital, I-29121 Piacenza, Italy.

PMID: 29552209 PMCID: PMC5840578 DOI: 10.3892/ol.2018.8054

Abstract

Central nervous system (CNS) metastases from cancers of the gastrointestinal tract (GIT) are rare, and occur in 0.16-0.69% of patients with gastric or gastro-esophageal (GE) junction cancer. Overexpression of the human epidermal growth factor 2 (HER-2) is associated with poor prognosis in the absence of HER-2-targeted therapy, and with an increased incidence of CNS metastases in patients with breast cancer. The role of HER-2 overexpression in CNS metastases is not well known in gastric adenocarcinoma. The purpose of the present retrospective study was to assess the incidence of CNS metastases and to evaluate the associations between the CNS and HER-2 status in a series of consecutive patients with gastric or GE junction cancer. Between 2007 and 2013, 300 patients with gastric cancer (GC) or gastroesophageal junction, were admitted to Piacenza General Hospital, Italy. These cases were retrospectively analyzed to evaluate CNS metastases. The metastases were diagnosed with imaging techniques performed on symptomatic patients. Gastric histological samples of patients with CNS metastases were reviewed and tested for HER-2. A total of 7 of the 300 patients (2.33%) with GC were observed to have CNS metastases and 6 (85.71%) had HER-2 positive disease. These patients exhibited a poor prognosis with a median overall survival rate of 4.1 months (range, 2.1-6.6 months). These results suggested there may be CNS recurrence susceptibility in patients with HER-2 positive GC. To the best of our knowledge, this is the first report that associates CNS metastases and HER-2 status in gastric or GE junction cancer.

Keywords: brain metastasis; central nervous system metastasis; gastric cancer; human epidermal growth factor 2 amplification; human epidermal growth factor 2 overexpression

References

  1. J Neurooncol. 2004 Jan;66(1-2):167-74 - PubMed
  2. Ann Oncol. 2006 Jun;17(6):935-44 - PubMed
  3. Anticancer Res. 2014 Dec;34(12 ):7357-60 - PubMed
  4. J Clin Oncol. 2011 May 1;29(13):e367-8 - PubMed
  5. Clin Cancer Res. 2009 Feb 15;15(4):1452-9 - PubMed
  6. J Gastric Cancer. 2017 Mar;17 (1):52-62 - PubMed
  7. Ann Surg Oncol. 1999 Dec;6(8):771-6 - PubMed
  8. Clin Cancer Res. 2007 Mar 15;13(6):1648-55 - PubMed
  9. World J Surg Oncol. 2017 Mar 21;15(1):68 - PubMed
  10. J Clin Oncol. 2008 Apr 20;26(12):1993-9 - PubMed
  11. Cancer. 2011 May 1;117(9):1837-46 - PubMed
  12. Acta Neuropathol. 2012 Feb;123(2):205-22 - PubMed
  13. Int J Clin Pract. 2014 Jul;68(7):890-9 - PubMed
  14. Cancer. 2011 Aug 15;117(16):3630-40 - PubMed
  15. Oncologist. 2009 Apr;14 (4):320-68 - PubMed
  16. Eur J Cancer. 2009 Nov;45(16):2792-8 - PubMed
  17. Breast Cancer Res. 2017 Apr 26;19(1):51 - PubMed
  18. J Clin Oncol. 2004 Sep 1;22(17):3608-17 - PubMed
  19. Surg Today. 2000;30(6):485-90 - PubMed
  20. Oncol Lett. 2014 Jul;8(1):394-396 - PubMed
  21. Oncol Lett. 2016 Apr;11(4):2893-2895 - PubMed
  22. Lancet. 2010 Aug 28;376(9742):687-97 - PubMed

Publication Types